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a b s t r a c t
We investigated the toxicity of synthetic antimicrobial decapeptide KSL-W on normal human gingival
epithelial cell cultures, its effect on Candida albicans adhesion and growth, and the activation of epithelial
cell innate immunity. Our results indicate that KSL-W had no toxic effect on cell adhesion or growth,
suggesting its safe use with human cells. Pre-treating C. albicans with KSL-W attenuated the yeast’s viru-
lence as demonstrated by its reduced adhesion and growth on engineered human oral mucosa epithelium
and the subsequent decreased expression of some innate defense molecules by targeted epithelial cells.
Indeed, the expression of Toll-like receptors and human -defensins was reduced in tissues infected with
KSL-W-treated Candida. Proinflammtory cytokine secretion (IL-1 and IL-6) by the epithelial cells was
also regulated by KSL-W in a manner similar to that of antifungal molecule amphotericin B. These findings
therefore show that KSL-W is safe for use with human cells and is able to attenuate Candida virulence by
modulating its effects on host innate immunity. This study proposes the potential application of KSL-W
peptide as an alternative antifungal agent.
© 2011 Elsevier Inc. All rights reserved.
1. Introduction
One of the most commonly encountered opportunistic microor-
ganisms in humans is Candida albicans [35], a yeast that is part
of the normal microbial flora found on mucosal surfaces such as
those of the oral cavity, gastrointestinal tract, and vagina in human
beings and domestic animals. This ubiquitous fungus is the most
common cause of mucosal and invasive fungal infections observed
in humans [29]. Host protection against Candida infection is com-
plex and includes different subsets of the immune defense system
[5,36,38,40].
Several recent studies have highlighted the significant role
played by the innate immunity of epithelial cells in prevent-
ing Candida infection of the oral mucosa. Primary epithelial cells
obtained from various sources [8,38,40] inhibit C. albicans growth
through cytokine and antimicrobial peptide expression [17,30,38].
The detection of and response to microbial infection by epithelial
cells is largely dependent on a family of pattern-recognition recep-
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tors called Toll-like receptors (TLRs) [41] which play an active role
in recognizing pathogens of considerable target specificity [26].
This recognition produces a series of signaling events that result
in the onset of acute host responses to ultimately contribute to
the killing of the pathogens [1]. Also demonstrated was the crucial
involvement of TLRs in the recognition of fungal pathogens such as
C. albicans, although less is known regarding the function of these
receptors following Candida infection [18,25]. The Candida-killing
activity of epithelial cells involves recognition of the organism by
TLR2 and TLR4 and the subsequent activation of NF-B [32].
Cell-mediated immunity (CMI) against Candida infection
involves various T lymphocyte subsets [15,36] that may dictate
the outcome of the infection. For example, Th1-type responses are
associated with resistance to gastrointestinal and systemic Candida
infections in animals, whereas Th2-type responses are associated
with susceptibility to the yeast infection [33]. CMI response against
Candida infection can be enhanced by humoral defense activity
mediated by Candida-specific antibodies, such as IgM, IgG, and IgA
[5].
A decrease in host defenses may lead to increased suscepti-
bility to Candida infections [35,40] which constitute a significant
public health challenge of high medical and socioeconomic impor-
tance. Although Candida infections are treatable with various
available drugs, such as polyenes (amphotericin B or nystatin),
azoles (voriconazole and posaconazole), and echinocandins (caspo-
0196-9781/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
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fungin, micafungin, anidulafungin) [21], the effectiveness of several
of these antifungal drugs is hampered by undesirable side effects
and the emergence of microbial resistance [7,13]. Antifungal drug
resistance has thus become a major concern for a growing num-
ber of immunocompromized individuals which has resulted in
a dramatic increase in the incidence of opportunistic and sys-
temic fungal infections. These facts have generated greater interest
toward developing new antifungal drugs using various synthetic
and naturally occurring antimicrobial molecules.
Natural antimicrobial peptides, such as defensins produced by
epithelial cells, are capable of a broad spectrum of antimicro-
bial characteristics and may play a role in preventing microbial
infections [8,19,45]. Generally, these antimicrobial peptides exhibit
selective toxicity for microorganisms and are less likely to
induce microbial resistance. In the pursuit of an alternative
antifungal treatment, we developed a synthetic -helical antimi-
crobial decapeptide, KSL (KKVVFKVKFK), and its analog KSL-W
(KKVVFWVKFK) [31], that not only display a wide range of antibac-
terial activity but were shown to effectively kill selected strains of
non-oral and oral pathogens, including streptococci mutans. In com-
bination with a surface-active agent, benzalkonium chloride, the
peptide significantly reduced in vitro biofilm growth [9,10,23,24].
We therefore sought to determine the potential of our syn-
thetic antimicrobial peptides, with a focus on the use of KSL-W
(a structurally more stable analog of KSL [31]) to control Candida
pathogenesis using engineered human oral mucosa as the target
host tissue. We also examined the toxicity of the peptide on oral
mucosa using gingival epithelial cell cultures.
2. Materials and methods
2.1. Human gingival epithelial cell and fibroblast cultures
Normal human gingival cells (epithelial cells and fibroblasts)
were obtained from ScienCell Research Laboratories (Carlsbad,
CA, USA). The fibroblasts were cultured in Dulbecco’s modified
Eagle’s medium (DME, Invitrogen Life Technologies, Burlington,
ON, Canada) supplemented with fetal bovine serum to a final
concentration of 10% (FBS, Gibco, Burlington, ON, Canada), peni-
cillin and streptomycin (20 g/ml), and fungizone (0.5 g/ml). The
epithelial cells were cultured in Dulbecco’s modified Eagle’s (DME)
– Ham’s F12 (3:1) (DMEH) with 5 g/ml of human transferrin,
2 nM 3,3′,5′ of triiodo-l-thyronine, 0.4 g/ml of hydrocortisone,
10 ng/ml of epidermal growth factor, penicillin and streptomycin,
and 10% FBS (final concentration). The medium was changed
three times a week. When the cultures reached 90% confluence,
the cells were detached from the flasks using a 0.05% trypsin-
0.1% ethylenediaminetetraacetic acid (EDTA) solution, washed
twice, and resuspended in DMEM (for the fibroblasts) or DMEH-
supplemented medium (for the epithelial cells). These were then
used for subsequent experiments.
2.2. Engineered human oral mucosa (EHOM) tissue
The EHOM model was produced as previously described [8,37].
Briefly, gingival fibroblasts and epithelial cells were used to form a
complex three-dimensional spatial cellular organization similar to
that found in normal human oral mucosa. The lamina propria was
produced by mixing Type I collagen (Gibco-Invitrogen, Burlington,
ON, Canada) with gingival fibroblasts, followed by culture in 10%
FBS-supplemented medium for four days. The lamina propria was
then seeded with gingival epithelial cells to obtain the EHOM. The
tissue specimens were grown under submerged conditions until
the total surface of the lamina propria was covered with epithelial
cells. To produce stratified epithelium, the EHOM was raised to an
air–liquid interface for four more days to facilitate the organization
of the epithelium into its different strata.
2.3. Effect of KSL-W on gingival epithelial cell adhesion
Epithelial cells (104 cells/well) were plated onto tissue culture-
grade cover glasses in six-well plates. Immediately after seeding,
various concentrations (0, 12.5, 50, and 100 g/ml) of KSL-W were
added to the medium and cultured in a humid atmosphere con-
taining 5% CO2 at 37 ◦C for 6 and 24 h. Controls include KSL-W
untreated epithelial cell cultures, and epithelial cells treated with
heat-inactivated (at 120 ◦C for 30 min) KSL-W. Following each time
point, the culture supernatants were removed and the cultures
were washed twice with warm medium, with adherent cells sub-
jected to Hoechst staining assay. The cells were incubated with
2 g/ml of Hoechst 33342 (H42) in PBS at room temperature for
15 min and were then washed extensively with PBS after which
time the stained cells were observed and photographed under an
epifluorescence microscope.
2.4. Effect of KSL-W on gingival epithelial cell viability/growth
Gingival epithelial cells (4 × 104 cells/well) were cultured in
appropriate medium in the presence of various concentrations
(12.5, 50 and 100 g/ml) of KSL-W. Controls include KSL-W
untreated epithelial cell cultures, and epithelial cells treated with
heat-inactivated (at 120 ◦C for 30 min) KSL-W. Monolayer cul-
tures were maintained in a 5% CO2 humid atmosphere at 37 ◦C for
24 and 72 h. Thereafter, cell proliferation was assessed using the
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
(MTT) assay (Sigma, St. Louis, MO, USA), which measures cell
growth as a function of mitochondrial activity [20]. MTT assay
is based on tetrazolium ring hydrolysis by mitochondrial dehy-
drogenase, which results in formazan, an insoluble blue reaction
product. Briefly, a stock solution (5 mg/ml) of MTT was prepared
in PBS and was added to each culture at a final concentration of
1% (v/v). Gingival epithelial cell cultures were incubated at 37 ◦C
for 4 h with the MTT solution. At the end of this culture period,
the supernatant was removed and the adherent cells were washed
twice using warm culture medium. Following the last wash, 2 ml
of 0.04 N HCl in isopropanol was added to each culture well, and
the incubation was extended for another 15 min. After this step,
200 l (in triplicate) of the reaction mixture was transferred to a
96-well flat-bottom plate and the absorbance (optical density, OD)
was measured at 550 nm using an enzyme-linked immunosorbent
assay (ELISA) reader (Model 680, Bio-Rad Laboratories, Mississauga,
ON, Canada). Results are reported as the means ± SD of six separate
experiments.
2.5. Growth of KSL-W-treated C. albicans on EHOM
C. albicans (SC5314) was inoculated into 10 ml Sabouraud dex-
trose broth (Difco; Becton-Dickinson) supplemented with 0.1%
glucose and was grown to the stationary phase overnight at 30 ◦C
in a shaking water bath. Following culture, blastoconidia were col-
lected, washed with PBS, counted by means of a hemocytometer
[38], and adjusted to 107 cells/ml. C. albicans (107 cells in 1 ml of
Sabouraud medium) was then incubated for 24 h with KSL-W at 0,
12.5, 50, and 100 g/ml, at 37 ◦C. As a positive control, C. albicans
was also cultured in the presence of amphotericin B at 5 g/ml.
For the negative control, C. albicans was cultured in the presence
of 100 g/ml of heat-inactivated (120 ◦C for 30 min) KSL-W pep-
tide. Following culture with or without KSL-W, Candida cells were
washed twice with PBS then 106 cells in 200 l of Sabouraud dex-
trose broth were overlaid on the top of the EHOM. After culture
for 24 h, the EHOMs were flipped onto Sabouraud dextrose agar
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Table 1
Primer sequences used for the q-RT-PCR.
Gene name Primers sequences Product size (bp)
TLR-2 Sense: 5′-GCCTCTCCAAGGAAGAATCC-3′ Antisense: 5′-TCCTGTTGTTGGACAGGTCA-3′ 144
TLR-4 Sense: 5′-AATCTAGAGCACTTGGACCTTTCC-3′Antisense: 5′-GGGTTCAGGGACAGGTCTAAAGA-3′ 116
TLR-6 Sense: 5′-CATCCTATTGTGAGTTTCAGGCAT-3′ Antisense: 5′-GCTTCATAGCACTACATCCCAAG-3′ 121
TLR-9 Sense: 5′-GGACCTCTGGTACTGCTTCCA-3′ Antisense: 5′-AAGCTCGTTGTACACCCAGTCT-3′ 151
1-Defensin Sense: 5′-GCCTCTCCCCAGTTCCTGAA-3′ Antisense: 5′-GCAGAGAGTAAACAGCAGAAGGTA-3′ 82
2-Defensin Sense: 5′-TGTGGTCTCCCTGGAACAAAAT-3′ Antisense: 5′-GTCGCACGTCTCTGATGAGG-3′ 105
3-Defensin Sense: 5′-CTTCTGTTTGCTTTGCTCTTCCT-3′ Antisense: 5′-CTGTTCCTCCTTTGGAAGGCA-3′ 138
4-Defensin Sense: 5′-CACTCTACCAACACGCACCTAG-3′ Antisense: 5′-CGCAACTGGAACCACACACT-3′ 133
GAPDH Sense: 5′-GGTATCGTCGAAGGACTCATGAC-3′ Antisense: 5′-ATGCCAGTGAGCTTCCCGTTCAGC-3′ 180
plates and left in place for 5 min. The EHOMs were then removed
and the plates were incubated for 24 h at 30 ◦C, after which time the
colony-forming-units (CFU) were counted. Results are reported as
the means ± SD of six separate experiments.
2.6. Effect of KSL-W-treated C. albicans on TLR and ˇ-defensin
gene expression by gingival epithelial cells in the EHOM
C. albicans (SC5314) was incubated in the presence or absence of
active KSL-W at various concentrations (12.5, 50 and 100 g/ml) or
heat-inactivated KSL-W (100 g/ml) for 24 h at 37 ◦C prior to use to
infect the EHMO, as described above. C. albicans (106 cells in 200 l
of Sabouraud medium) was laid on top of each engineered mucosa
sample. The tissues were then incubated in a 5% CO2 humid atmo-
sphere for 12 h at 37 ◦C. Following incubation, each EHOM tissue
was washed twice with fresh medium and thereafter, the epithelia
were detached from the lamina propria and used to extract total
RNA.
2.7. RNA extraction and quantification
Total cellular RNA was extracted using the Illustra RNAspin Mini
(GE Health Care UK Limited, Buckingham, UK). The concentration,
purity, and quality of the isolated RNA were all determined using
the Experian system and RNA StdSens analysis kit according to
instructions provided by the manufacturer (Bio-Rad, Hercules, CA,
USA).
2.8. Quantitative real-time RT-PCR
RNA (1 g of each sample) was reverse transcripted into cDNA
using Maloney murine leukemia virus (M-MLV) reverse transcrip-
tase (Invitrogen Life Technologies, Mississauga, ON, Canada) and
random hexamers (Amersham Pharmacia Biotech, Inc., Baie d’Urfé,
QC, Canada). The conditions for the preparation of the cDNA tem-
plates for PCR analysis were 10 min at 65 ◦C, 1 h at 37 ◦C, and
10 min at 65 ◦C. Quantitative PCR (qPCR) was carried out as previ-
ously described [3]. Amounts of mRNA transcripts were measured
using the Bio-Rad CFX96 real-time PCR detection system. Reac-
tions were performed using a PCR supermix from Bio-Rad (iQ
SYBR Green supermix). Primers (Table 1) were added to the reac-
tion mix at a final concentration of 250 nM. Five microlitres of
each cDNA sample was added to a 20 l PCR mixture containing
12.5 l of iQ SYBR Green supermix (Bio-Rad) and 0.5 l of spe-
cific primers (TLR2, TLR4, TLR6, TLR9, HBD1, HBD2, HBD3, HBD4,
or GAPDH) (Medicorp, Inc., Montréal, QC, Canada) and 7 l of
RNase/DNase-free water (MP Biomedicals, Solon, OH, USA). Each
reaction was performed in a Bio-Rad MyCycler Thermal Cycler. For
the qPCR, the CT was automatically determined using the accom-
panying Bio-Rad CFX manager. The thermocycling conditions for
the TLRs were established as 5 min at 95 ◦C, followed by 45 cycles
of 15 s at 95 ◦C, 30 s at 60 ◦C, and 30 s at72 ◦C, with each reac-
tion done in triplicate. For the HBDs, the thermocycling conditions
were 3 min at 95 ◦C, followed by 45 cycles of 10 s at 95 ◦C, 10 s at
63 ◦C, and 30 s at 72 ◦C, with each reaction performed in triplicate.
The specificity of each primer pair was verified by the presence
of a single melting temperature peak. GAPDH produced uniform
expression levels varying by less than 0.5 CTs between sample
conditions and was therefore used as a reference gene for this
study.
2.9. Western blot analyzes of TLR production following EHOM
contact with KSL-W-treated C. albicans
Following contact with KSL-W treated Candida for 24 h, as
described above, each EHOM tissue was washed twice with fresh
medium and thereafter, the epithelia were detached from the
lamina propria and total proteins were extracted using lysis
buffer (50 mM of HEPES, pH 7.4; 1% (v/v) Triton X-100; 4 mM of
EDTA; 1 mM of sodium fluoride; 0.1 mM of sodium orthovanadate;
1 mM of tetrasodium pyrophosphate; 2 mM of phenylmethylsul-
fonyl fluoride; 10 g/ml of leupeptin; and 10 g/ml of aprotinin).
The lysates were incubated for 60 min on ice and then vor-
texed, with the insoluble materials removed by centrifugation
(14,000 × g, 2 min, 4 ◦C). The protein lysates were subsequently
used for immunoblotting. Whole cell lysates (40 g of total pro-
tein) were subjected to SDS polyacrylamide gel electrophoresis and
were electroblotted onto PVDF membranes (pore size 0.2 m). The
membranes were blocked with 5% BSA in Tween-20/Tris-buffered
saline (TBS) (TTBS; Tris-buffered saline, 0.1% Tween-20) for 1 h at
ambient temperature and were incubated overnight at 4 ◦C with
primary anti-TLR2 (1:250, Imgenex, San Diego, USA), anti-TLR4
(1:200, Imgenex, San Diego, USA), anti-TLR6 (1:200, R&D Systems,
Minneapolis, USA), anti-TLR9 (1:500, Cell Signaling, Danvers, MA,
USA) and anti-actin (1:5000) antibodies in TTBS containing 0.5%
BSA. The membranes were washed three times with TTBS for 10 min
after which time they were incubated with horseradish peroxidase
labeled secondary antibody (1:1000 in TTBS) for 1 h at ambient tem-
perature. For protein detection, the membranes were washed for
3 h with TBS, were subsequently incubated in ECL (Amersham), and
were assessed by means of a FujiFilm Image Reader LAS-1000 Pro
(FujiFilm USA, Valhalla, NY, USA). The experiment was repeated
four separate times.
2.10. Measurement of IL-1ˇ, IL-6, and IL-8 secretion following
interaction of KSL-W-treated C. albicans with the EHOM
To determine the protein levels of cytokines IL-1, IL-6, and
IL-8, supernatants obtained from the EHOM following their infec-
tion with KSL-W-treated C. albicans for 24 h were analyzed by
sandwich enzyme-linked immunosorbent assays (ELISA, R&D Sys-
tem, Minneapolis, MN). The supernatants were collected in tubes
containing 1 l of a protease inhibitor cocktail for specific use
with mammalian cell and tissue extracts (Sigma–Aldrich). Imme-
diately after, the supernatants were filtered through 0.22 m
filters and used either undiluted or at a dilution of 1/50 in PBS
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Fig. 1. Photomicrograph of the epithelial cell monolayer cultures following treatment with KSL-W. No effect on cellular adhesion was observed after 6 and 24 h culture
periods. Photos are representative of five separate experiments.
to measure cytokine levels. ELISA plates were read at 450 nm
and were analyzed using a Microplate Reader Model 680 (Bio-
Rad, USA). The minimum detectable concentrations were under
1 pg/ml for the IL-1, 0.7 pg/ml for the IL-6, and 3.5 pg/ml for
the IL-8, as reported by the manufacturer. Each experiment was
repeated four times and the means ± SD were calculated and
presented.
2.11. Statistical analyzes
Each experiment was performed at least four times, with exper-
imental values expressed as means ± SD. The statistical significance
of the differences between the control (absence of KSL-W) and the
test (presence of KSL-W) values was determined by means of a
one-way ANOVA. Posteriori comparisons were done using Tukey’s
method. Normality and variance assumptions were verified using
the Shapiro-Wilk test and the Brown and Forsythe test, respec-
tively. All of the assumptions were fulfilled. P values were declared
significant at ≤0.05. Data were analyzed using the SAS version 8.2
statistical package (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. KSL-W had no inhibitory effect on gingival epithelial cell
adhesion
Fig. 1 shows that KSL-W had no effect on cell morphology at con-
centrations ranging from 12.5 to 100 g/ml as well as no effect on
the adhesion of cultured epithelial cells. In addition, no difference in
cell density was observed in the epithelial cells cultured in the pres-
ence or absence of KSL-W. Heat-inactivated KSL-W has no effect on
epithelial cell adhesion (Fig. 1). These results clearly demonstrate
the absence of any toxic effect of KSL-W on the adhesion of cultured
epithelial cells.
3.2. KSL-W had no side effect on gingival epithelial cell
proliferation
As shown in Fig. 2, epithelial cell growth at 24 h post-treatment
with KSL-W was comparable to that recorded by the untreated cul-
ture, with an optical density ranging from 0.7 to 0.8. After 72 h
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Fig. 2. Effect of KSL-W on human gingival epithelial cell proliferation. Following
epithelial cell culture in the presence or not of KSL-W for 24 and 72 h, each cul-
ture was subjected to an MTT assay. Cell proliferation was assessed by means
of absorbance measurements. Note that no effect on cellular proliferation was
observed in the presence of different test concentrations of KSL-W antimicrobial
peptide. Heat-inactivated KSL-W has also no effect on cell growth.
of culture, epithelial cell growth increased equally in the control
group and the KSL-W-treated group. Heat-inactivated KSL-W did
not affect epithelial cell proliferation (Fig. 2).
3.3. KSL-W pre-treatment reduced Candida growth in the
infected oral mucosa tissue
Fig. 3 shows that the growth of C. albicans was significantly
inhibited by the KSL-W pre-treatment, compared to that of the
untreated control. A dose response of the KSL-W pre-treatment
Fig. 3. Adhesion and growth of KSL-W-treated C. albicans on the EHOM. The
pre-treatment of C. albicans decreased its adhesion and growth on the EHOM. KSL-
W-untreated Candida, Candida treated with 5 g/ml of amphotericin B are shown
for comparison with 12.5, 50 and 100 g/ml KSL-W pre-treated Candida. Results
represent means ± SD of four different experiments.
was also observed, as the number of CFUs recovered decreased
from 170 ± 13 CFUs/cm2 to 12 ± 2 CFUs/cm2 when the Candida cells
were pre-treated with 12.5 g/ml and 100 g/ml of KSL-W, respec-
tively. Heat-inactivated KSL-W showed no effect on Candida growth
(Fig. 3).
3.4. KSL-W modulated TLRs expression by the EHOM gingival
epithelial cells following contact with C. albicans
RT-PCR results indicate that when the EHOM was cultured in the
presence of KSL-W-treated C. albicans, TLR2 mRNA expression was
Fig. 4. TLR expression by gingival epithelial cells following infection by KSL-W-treated C. albicans. Pre-treating C. albicans with KSL-W reduced its ability to induce TLR2, 4, 6,
and 9 gene expression. Results are presented as the number of fold increase in expression of the genes in the test samples compared to that in the control. Data are expressed
as means ± SD from triplicate assays of three different experiments.
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reduced by approximately five fold as compared to the expression
level exhibited by the EHOM cultured in the presence of untreated
Candida. This reduction occurred in a dose-dependent manner
(Fig. 4). Similar results were obtained with TLR4 expression. When
C. albicans was pre-treated with KSL-W, TLR4 mRNA expression
by the epithelial cells significantly decreased, contrasting that
of the EHOM epithelial cells infected with untreated Candida.
This decrease in expression level appeared to be dose-dependent
(Fig. 4). Thus KSL-W reduced C. albicans virulence, leading to a
down regulation of TLR4 expression by the EHOM epithelial cells.
TLR9 is also a key receptor implicated in pathogen recognition
by epithelial cells. C. albicans-treated KSL-W significantly reduced
TLR9 mRNA expression by the EHOM compared to the expression
recorded by the tissues infected with untreated C. albicans (Fig. 4).
This significantly inhibited expression was observed by the pre-
treatment of Candida with KSL-W at 50 and 100 g/ml. In contrast
to the previously described TLRs, TLR6 expression was up regu-
lated when the EHOM was infected with KSL-W-treated C. albicans
(Fig. 4). The increased TLR6 mRNA expression was obtained with
50 and 100 g/ml of KSL-W and was comparable to the expres-
sion obtained with the ampho-B-treated C. albicans, suggesting that
both KSL-W and ampho-B modulated TRL6 mRNA expression by
the gingival epithelial cells in a similar fashion. As shown in Fig. 4,
KSL-W and ampho-B had the same effect on TLR2, TLR4, and TLR9
mRNA expression by the EHOM gingival epithelial cells following
C. albicans infection. Heat-inactivated KSL-W pre-treated Candida
showed no effect on the expression of TLRs by EHOM epithelial
cells (Fig. 4). Protein analyzes using Western blot (Fig. 5) confirmed
the mRNA expression results. Indeed, TLR2, TLR4 and TLR9 pro-
teins were reduced in EHOMs infected with KSL-W treated Candida
(Fig. 5). In contrast, TLR6 protein was increased basically with 50
and 100 g/ml of KSL-W (Fig. 5).
Fig. 5. TLR protein production by gingival epithelial cells following infection by KSL-
W-treated C. albicans. Western blot analysis of TLR2, TLR4, TLR6 and TLR9 proteins
following EHOMs contact with untreated and KSL-W treated Candida (n = 4).
3.5. KSL-W downregulated the effect of C. albicans on human
ˇ-defensin expression
As shown in Fig. 6, when Candida was pre-treated with KSL-W
at 12.5 and 50 g/ml, HBD1 mRNA expression was unchanged, yet
it was reduced in the EHOM gingival epithelial cells when treated
with KSL-W at 100 g/ml. Similarly, Candida pre-treated with KSL-
W at 50 and 100 g/ml reduced HBD2 mRNA expression by the
epithelial cells (Fig. 6). Also, EHOM infected with KSL-W pre-treated
Fig. 6. -Defensin expression gingival epithelial cells following contact with KSL-W pre-treated C. albicans. Pre-treating the yeast with KSL-W resulted in reduced HBD1,
HBD2, HBD3, and HBD4 gene expression by the EHOM epithelial cells following infection. The decreased level of -defensin expression is similar to that observed with the
amphotericin B-treated yeast cells. Results are presented as the number of fold increase in expression of the genes in the test sample compared to the gene expression in the
control. Data are expressed as means ± SD from triplicate assays of three different experiments.
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Fig. 7. Cytokine secretion by the gingival epithelial cells following C. albicans infec-
tion. Increased IL-1 (A) and decreased IL-6 (B) secretions were observed in the
EHOM gingival epithelial cells infected with KSL-W pre-treated C. albicans. KSL-W
at high concentrations, and amphotericin B effects were comparable. Data are the
means ± SD of four separate experiments.
C. albicans, showed reduced levels of both HBD3 and HBD4 mRNA
expression (Fig. 6). It should be noted that the antifungal molecule
ampho-B had an effect comparable to that of KSL-W on HBD1, 2,
3, and 4 mRNA expressions (Fig. 6). Heat-inactivated KSL-W pre-
treated Candida showed no effect in human -defensins expression.
3.6. Cytokine induction
As shown in Fig. 7A, following EHOM infection with KSL-W pre-
treated C. albicans for 24 h, the secretion of IL-1 was significantly
increased basically with 50 and 100 g/ml of KSL-W. This effect
was similar to the one obtained with ampho-B (Fig. 7a). Inactivated
KSL-W pre-treated Candida showed similar effect as non-infected
EHOM. By contrast, the secretion of IL-6 significantly decreased
after 24 h of contact of EHOM with the KSL-W pre-treated Can-
dida (Fig. 7B). Decreases of IL-6 secretion was important when
KSL-W was used at 50 and 100 g/ml. At high concentration, the
KSL-W effect was comparable to the one obtained with ampho-B-
treated Candida treated EHOM. A study performed on IL-8 secretion
showed no significant modulation of this chemokine. Results sug-
gest that KSL-W may potentially modulate cell defenses against
infection through IL-1 and IL-6. When a higher concentration
(100 g/ml) of KSL-W was used, the effect was also comparable
to that of ampho-B. However, the effects of KSL-W on IL-1 and
IL-6 secretions are different.
4. Discussion
Antimicrobial peptides displaying in vitro activity against
human bacterial pathogens [28] have been proposed as a novel
control strategy to combat bacterial infections [27,34] and an alter-
native solution to control fungal infections [27,28,34]. As some
available antifungal agents are ineffective (in terms of resistance)
and may cause significant side effects, the medical community is
now turning its interest toward new anti-fungal molecules. Nat-
urally occurring antimicrobial peptides (AMPs) have been shown
to play an essential protective role against microbial infections in
species across the animal and plant kingdoms.
Synthetic peptides that mimick many of the key structural fea-
tures essential for the antimicrobial activity of naturally occurring
AMPs have emerged as substitutes against microbial infections.
Our laboratories have focused on the antimicrobial activity of syn-
thetic decapeptide KSL and its structural analog KSL-W. We in fact
discovered that these peptides possess potent antimicrobial activ-
ity against a wide variety of oral and non-oral bacterial pathogens
[6,10]. However, their potential effect against fungi, such as C. albi-
cans, remains to be determined.
Oral candidiasis is associated with gingival tissue where epithe-
lial cells are the primary components of the oral mucosa [11,16,38].
We sought to determine the effect of antimicrobial peptide KSL-
W in controlling oral candidiasis and its toxicity, if any, against
oral mucosa cells. Our results show that at both low and high
concentrations, KSL-W had no effect on the adhesion and prolif-
eration of monolayer cultures of gingival epithelial cells. These
findings, reported here for the first time, demonstrate that decapep-
tide KSL-W exhibited no toxicity against human gingival epithelial
cells.
To determine the potential effect of antimicrobial KSL-W against
oral candidiasis, we produced an engineered oral mucosa to mim-
ick the in vivo conditions in which the yeast is in contact with
the host tissue. In this context, engineered oral mucosa was cul-
tured in the presence of C. albicans which was pre-treated or not
with various concentrations of antimicrobial peptide KSL-W. We
found that KSL-W downregulated the adhesion and growth of
C. albicans on the EHOM. Compared to the control, the number
of C. albicans CFUs had significantly decreased following treat-
ment with KSL-W at concentrations of 50 and 100 g/ml. These
results therefore demonstrate the growth-inhibiting effect of KSL-
W against Candida. Similar results were previously observed using
other antimicrobial peptides such as human -defensins [8,14].
Although we did demonstrate that antimicrobial peptide KSL-W
may inhibit Candida growth, the mechanism by which it reduces
this growth remains to be determined.
It is well documented that epithelial cells play an active role in
protecting the host against invading microbial pathogens. Recent
studies have demonstrated the possible involvement of TLRs in the
recognition, by epithelial cells, of fungal pathogens including Can-
dida species [2,19,26]. The present study links TLR activation in oral
epithelial cells to C. albicans infection using a human oral mucosa
model and the ability of KSL-W to attenuate the capacity of Candida
activating the innate immunity.
Quantitative real-time RT-PCR revealed that the gingival epithe-
lial cells expressed TLR2, TLR4, and TLR9 following infection with
C. albicans. However, following KSL-W treatment of the yeast, the
expression of these TLRs from the targeted epithelial cells was
downregulated. These data support those showing that epithelial
cells respond to microbial infections through TLRs [2,22,42]. As
in the case of antifungal drugs such as ampho-B, KSL-W down-
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regulated Candida virulence, which in turn modulated the innate
response of the epithelial cells through decreased TLR2, TLR4, and
TLR9 gene and protein expression.
It remains unclear whether the decreased TRL expression by the
epithelial cells was due to the change of surface phenotypes or the
loss of viability of Candida following pre-treatment with KSL-W.
These changes may in fact contribute to its reduced ability to elicit
host innate responses. On the other hand, the observed results may
also indicate the ability of epithelial cells to sense and distinguish
differences between microbial challenges encountered (for exam-
ple, virulent versus avirulent strains or dead organisms), resulting
in various levels of subsequent activation of host innate responses.
Further studies will elucidate the underlying mechanistic inter-
action(s) between KSL-W treated Candida and gingival epithelial
cells that lead to this decrease in TLR expression. Of interest
is that while a decrease was observed in TLR2, TLR4, and TLR9
expression due to pre-treatment with the peptide, TLR6 expres-
sion increased in the targeted cells. Similar results were obtained
by treating specific organisms with natural molecules, such as gar-
lic [44], and quorum-sensing inhibitory molecules, such as farnesol
[8].
Recognition of pathogen-associated molecular patterns of
invading microbial organisms by epithelial cells through TLRs can
lead to the expression, by these cells, of native antimicrobial pep-
tides such as HBDs [43]. In this study, we confirm that gingival
epithelial cells may prevent C. albicans infection by expressing
various HBDs. Interestingly, the KSL-W-treated C. albicans demon-
strated less virulence as evidenced by a reduced activation of
epithelial cells through reduced HBD expression. This effect was
similar to that obtained with antifungal agents, such as ampho-
tericin B, which are used clinically to control Candida infection.
These results suggest that KSL-W attenuated Candida virulence,
thus when it came in contact with epithelial cells, the latter were
able to sense the avirulent nature of the challenge, which led to a
reduced expression of HBDs as a part of the host’s inflammatory
response to infection.
In addition to the role epithelial cells have in controlling Can-
dida pathogenesis through the expression of native antimicrobial
peptides, several studies have reported that these cells display
innate immunity against bacterial and yeast infections via an active
inflammatory process that involves a variety of mediators includ-
ing IL-1, IL-6, and IL-8 [12,38,39]. Given the biological role of oral
epithelial cells as active immunocytes [4] because of their ability to
secrete several pro-inflammatory cytokines, our study shows that
the production of both IL-1 and IL-6 were modulated following
contact with the KSL-W-treated C. albicans. The peptide increased
IL-1, but decreased IL-6 secretions. These effects of KSL-W were
comparable to that obtained with amphotericin B. Our data sug-
gest that KSL-W modulated the host pro-inflammatory responses
against C. albicans through different ways involving IL-1 and IL-
6. Further investigations will therefore be necessary to identify
the signaling pathway activated by KSL-W-treated Candida which
results in a selective increase/decrease of IL-1 and IL-6 production.
5. Conclusion
Our study confirms the non-toxic effect of KSL-W on normal
human gingival epithelial cells and its ability to inhibit the adhe-
sion and growth of C. albicans on engineered human oral mucosa.
KSL-W was also shown to reduce C. albicans virulence/pathogenesis
by reducing C. albicans ability to activate the innate immunity
exhibited by the targeted epithelial cells. Overall results suggest
that KSL-W may have antipathogenic properties and may show
potential as an antifungal molecule to treat infections such as oral
candidiasis.
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